Curaleaf Resumes CURLF Trading After Reverse-Split Transition

Curaleaf Holdings, one of the largest U.S. multistate cannabis operators, said its subordinate voting shares returned to the OTC ticker CURLF on July 6, 2026, ending a temporary trading symbol that had flagged the company’s recent reverse stock split. The switch is administrative, requiring no shareholder action, but it closes the last mechanical step of a share consolidation Curaleaf ran to ready itself for a possible listing on a U.S. stock exchange.

For about four weeks after its split took effect, Curaleaf’s stock traded on the OTCQX Best Market under the placeholder symbol CURLD. The “D” suffix is a routine market convention: FINRA and OTC Markets Group attach it for 20 trading days after a corporate action to flag that a company’s share structure has changed. With that window closed, the shares reverted to CURLF. The company’s Toronto Stock Exchange listing, under the symbol CURA, was never interrupted.

The reverse split behind the ticker

The symbol swap traces to a reverse stock split that took effect June 5, 2026. On a one-for-three basis, every three subordinate voting shares combined into one, cutting Curaleaf’s outstanding subordinate voting shares from about 698.7 million to roughly 232.9 million. The mechanics are neutral to what an investor actually owns: the same stake in the company, held across fewer shares at a proportionally higher price, with the company’s overall market value unchanged. Curaleaf’s board approved the consolidation without a shareholder vote, which its governing corporate statute did not require, and the Toronto Stock Exchange granted conditional approval.

For most investors the transition was invisible. Shares held through a broker or bank were adjusted automatically; only registered holders who own paper certificates or sit on the company’s direct-registration system need to return them, with a letter of transmittal, to transfer agent Odyssey Trust Company. Curaleaf has also said the split is not expected to be a taxable event for U.S. or Canadian shareholders, whose cost basis simply spreads across fewer shares.

Aimed at a U.S. exchange

The purpose of the exercise is share price. Major U.S. exchanges set minimum listing prices, and many retail brokerages restrict or discourage trading in sub-dollar stocks. By reducing the share count, Curaleaf lifts its per-share price into a range that clears those bars and, the company argues, widens the base of institutional investors that can hold the stock. Chairman and CEO Boris Jordan framed the July 6 reset as continuity for shareholders, saying the company remains “focused on strengthening [its] capital markets profile and positioning the company for future opportunities as the regulatory and exchange-listing landscape continues to evolve.”

That landscape shifted in April 2026, when federal officials reclassified FDA-approved and state-licensed medical cannabis to Schedule III, a change that for the first time opened a plausible route for plant-touching cannabis companies onto U.S. exchanges that had refused to list them. Curaleaf is one of several large operators repositioning around that opening. Trulieve became the first U.S. operator to win a New York Stock Exchange listing, and Glass House (GLAS ) Brands secured its own NYSE approval. Verano completed a 1-for-5 consolidation, TerrAscend (TSND.TO ) called a shareholder meeting to authorize one, and Vireo Growth set a 30-for-1 ratio, each citing the same U.S.-listing goal.

Preparation, not a listing

For Curaleaf, the reverse split is groundwork rather than a listing. The company has not named a U.S. exchange, a ticker, or a date; its own investor materials describe an uplisting as an opportunity to pursue “if and when it arises.” The conditions it is waiting on remain unsettled. A broader federal hearing on rescheduling all cannabis, not just medical products, ran into mid-July 2026, and the U.S. Treasury tax guidance the industry has been promised has yet to appear. The government’s posture on cannabis taxes is also still contested, as the Justice Department’s suit to claw back a cannabis tax refund shows.

The stakes explain the preparation. A major-exchange listing would give an operator like Curaleaf, whose international arm reaches across Europe, Canada and Australasia alongside its U.S. business, access to deeper liquidity, a wider institutional shareholder base, and a lower cost of capital than the over-the-counter market offers. What is confirmed today is narrower: the split is done, the ticker is restored, and Curaleaf’s shares trade in Toronto as CURA and over the counter as CURLF, as they did before. Whether that scaffolding becomes a Nasdaq or NYSE listing rests with federal regulators and the exchanges.